Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors
C Simoens, PPL Martin‐Hirsch - Cochrane database of …, 2018 - cochranelibrary.com
Background Persistent infection with high‐risk human papillomaviruses (hrHPV) types is
causally linked with the development of cervical precancer and cancer. HPV types 16 and …
causally linked with the development of cervical precancer and cancer. HPV types 16 and …
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the …
D Saslow, D Solomon, HW Lawson… - American journal of …, 2012 - academic.oup.com
An update to the American Cancer Society (ACS) guideline regarding screening for the early
detection of cervical precancerous lesions and cancer is presented. The guidelines are …
detection of cervical precancerous lesions and cancer is presented. The guidelines are …
[HTML][HTML] Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)
LE Markowitz, EF Dunne, M Saraiya, HW Chesson… - MMWR Recomm …, 2014 - cdc.gov
This report summarizes the epidemiology of human papillomavirus (HPV) and associated
diseases, describes the licensed HPV vaccines, provides updated data from clinical trials …
diseases, describes the licensed HPV vaccines, provides updated data from clinical trials …
Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development
N Kushnir, SJ Streatfield, V Yusibov - Vaccine, 2012 - Elsevier
Virus-like particles (VLPs) are a class of subunit vaccines that differentiate themselves from
soluble recombinant antigens by stronger protective immunogenicity associated with the …
soluble recombinant antigens by stronger protective immunogenicity associated with the …
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age
X Castellsagué, N Muñoz, P Pitisuttithum… - British journal of …, 2011 - nature.com
Background: Previous analyses from a randomised trial in women aged 24–45 years have
shown the quadrivalent human papillomavirus (qHPV) vaccine to be efficacious in the …
shown the quadrivalent human papillomavirus (qHPV) vaccine to be efficacious in the …
Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data
EA Joura, SM Garland, J Paavonen, DG Ferris, G Perez… - Bmj, 2012 - bmj.com
Objectives To determine the effect of human papillomavirus (HPV) quadrivalent vaccine on
the risk of developing subsequent disease after an excisional procedure for cervical …
the risk of developing subsequent disease after an excisional procedure for cervical …
Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine
SM Garland, M Steben, HL Sings… - The Journal of …, 2009 - academic.oup.com
Background The placebo arm of human papillomavirus (HPV) vaccine trials helps define the
natural history of genital warts (GW) Methods Women enrolled in the placebo arm (n= 8800) …
natural history of genital warts (GW) Methods Women enrolled in the placebo arm (n= 8800) …
[HTML][HTML] Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and …
Future I/II Study Group - The BMJ, 2010 - ncbi.nlm.nih.gov
Objectives To evaluate the prophylactic efficacy of the human papillomavirus (HPV)
quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial …
quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial …
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised …
N Muñoz, R Manalastas, P Pitisuttithum, D Tresukosol… - The Lancet, 2009 - thelancet.com
Background Although the peak incidence of human papillomavirus (HPV) infection occurs in
most populations within 5–10 years of first sexual experience, all women remain at risk for …
most populations within 5–10 years of first sexual experience, all women remain at risk for …
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine …
DR Brown, SK Kjaer, K Sigurdsson… - The Journal of …, 2009 - academic.oup.com
Abstract Background Human papillomavirus (HPV)–6/11/16/18 vaccine reduces the risk of
HPV-6/11/16/18–related cervical intraepithelial neoplasia (CIN) 1–3 or adenocarcinoma in …
HPV-6/11/16/18–related cervical intraepithelial neoplasia (CIN) 1–3 or adenocarcinoma in …